At the time of writing, Supernus Pharmaceuticals Inc [SUPN] stock is trading at $56.5, up 1.47%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SUPN shares have gain 8.61% over the last week, with a monthly amount glided 17.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Supernus Pharmaceuticals Inc [NASDAQ: SUPN] stock has seen the most recent analyst activity on October 09, 2025, when Piper Sandler upgraded its rating to a Overweight but kept the price target unchanged to $65 for it. Previously, Cantor Fitzgerald upgraded its rating to Overweight on July 30, 2025, and kept the price target unchanged to $42. On February 19, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $36 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $57 on January 06, 2025. Piper Sandler downgraded its rating to a Neutral and reduced its price target to $36 on September 11, 2024.
For the past year, the stock price of Supernus Pharmaceuticals Inc fluctuated between $29.16 and $55.94. Currently, Wall Street analysts expect the stock to reach $64 within the next 12 months. Supernus Pharmaceuticals Inc [NASDAQ: SUPN] shares were valued at $56.5 at the most recent close of the market. An investor can expect a potential return of 13.27% based on the average SUPN price forecast.
Analyzing the SUPN fundamentals
According to Supernus Pharmaceuticals Inc [NASDAQ:SUPN], the company’s sales were 665.12M for trailing twelve months, which represents an -1.71% plunge. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.1%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.06 and Total Capital is 0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 55.13 points at the first support level, and at 53.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 57.76, and for the 2nd resistance point, it is at 59.02.
Ratios To Look Out For
It is important to note that Supernus Pharmaceuticals Inc [NASDAQ:SUPN] has a current ratio of 2.58. In addition, the Quick Ratio stands at 2.43 and the Cash Ratio stands at 0.51. Considering the valuation of this stock, the price to sales ratio is 4.76, the price to book ratio is 2.98 and price to earnings (TTM) ratio is 49.38.
Transactions by insiders
Recent insider trading involved Khattar Jack A., President, CEO, that happened on Oct 09 ’25 when 59900.0 shares were sold. Director, NEWHALL CHARLES W III completed a deal on Oct 09 ’25 to sell 25000.0 shares. Meanwhile, Director JACK A. KHATTAR bought 59900.0 shares on Oct 09 ’25.
